These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23594312)

  • 41. AIDS in the Third World: how to stop the HIV infection?
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?
    Hankins CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):167-70. PubMed ID: 24552641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study.
    Fowler N; Arkell P; Abouyannis M; James C; Roberts L
    AIDS Patient Care STDS; 2015 Jan; 29(1):33-42. PubMed ID: 25375792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPTN 052 and the future of HIV treatment and prevention.
    Seale A; Lazarus JV; Grubb I; Fakoya A; Atun R
    Lancet; 2011 Jul; 378(9787):226. PubMed ID: 21763932
    [No Abstract]   [Full Text] [Related]  

  • 45. Role of medication therapy management in preexposure prophylaxis therapy for HIV prevention.
    Ferrell KW; Woodard LM; Woodard TJ
    J Pharm Pract; 2015 Feb; 28(1):10-2. PubMed ID: 25500557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What does preexposure prophylaxis mean for treatment; what does treatment mean for preexposure prophylaxis?
    Venter WD
    Curr Opin HIV AIDS; 2016 Jan; 11(1):35-40. PubMed ID: 26545265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiretrovirals for HIV prevention: when should they be recommended?
    Kiselinova M; De Spiegelaere W; Verhofstede C; Callens SF; Vandekerckhove L
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):431-45. PubMed ID: 24621251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection.
    Arya V; Au S; Belew Y; Miele P; Struble K
    Curr Opin HIV AIDS; 2015 Jul; 10(4):278-81. PubMed ID: 26049954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre-exposure prophylaxis--one more tool for HIV prevention.
    Person AK; Hicks CB
    Curr HIV Res; 2012 Mar; 10(2):117-22. PubMed ID: 22329517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is new in HIV infection?
    Sherin K; Klekamp BG; Beal J; Martin N
    Am Fam Physician; 2014 Feb; 89(4):265-72. PubMed ID: 24695446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ARV-based HIV prevention for women - where we are in 2014.
    Mastro TD; Sista N; Abdool-Karim Q
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19154. PubMed ID: 25224614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomedical strategies for human immunodeficiency virus (HIV) prevention? A new paradigm.
    Chan R
    Ann Acad Med Singap; 2012 Dec; 41(12):595-601. PubMed ID: 23303118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HPTN 052 and the future of HIV treatment and prevention.
    Epstein H; Morris M
    Lancet; 2011 Jul; 378(9787):225. PubMed ID: 21763929
    [No Abstract]   [Full Text] [Related]  

  • 54. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings.
    Abbas UL; Anderson RM; Mellors JW
    PLoS One; 2007 Sep; 2(9):e875. PubMed ID: 17878928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiretroviral therapy for prevention of HIV transmission: potential role for people who inject drugs in Central Asia.
    McNairy ML; Deryabina A; Hoos D; El-Sadr WM
    Drug Alcohol Depend; 2013 Nov; 132 Suppl 1():S65-70. PubMed ID: 23880248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation.
    Matthews LT; Baeten JM; Celum C; Bangsberg DR
    AIDS; 2010 Aug; 24(13):1975-82. PubMed ID: 20679759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Long-term impact of antiretroviral therapy in Africa: current knowledge].
    Taverne B; Desclaux A; Delaporte E; Ndoye I
    Bull Soc Pathol Exot; 2014 Oct; 107(4):222-9. PubMed ID: 25204573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Turning the tide against AIDS by preventing new HIV infections initial experience with Minnesota's first PrEP clinic.
    Eccles-Radtke C; Henry K
    Minn Med; 2015 Jan; 98(1):45-8. PubMed ID: 25665269
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-exposure prophylaxis in Southern Africa: feasible or not?
    Venter WD; Cowan F; Black V; Rebe K; Bekker LG
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19979. PubMed ID: 26198344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nurturing the Continuum of HIV Testing, Treatment and Prevention Matrix Cascade in Reducing HIV Transmission.
    Yah CS
    Ethiop J Health Sci; 2017 Nov; 27(6):621-630. PubMed ID: 29487471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.